Pilot trial of ZD1839 (IressaTM), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC)

作者： S.A Laurie , V.A Miller , D Johnson , K.K Ng , R.T Heelan

DOI: 10.1016/S0169-5002(00)80230-5

关键词: Oncology 、 non-small cell lung cancer (NSCLC) 、 Pilot trial 、 Tyrosine kinase 、 Egfr tyrosine kinase 、 Epidermal growth factor receptor 、 Carboplatin 、 Internal medicine 、 Medicine 、 Paclitaxel